Pharmalot - STAT

Pharmalot By Ed Silverman

Pharmalittle: Biden to spend $3 billion to develop Covid-19 pills; most Americans believe the new Alzheimer’s drug will be effective

Pharmalot By Ed Silverman

Poll: Most Americans believe new Alzheimer’s drug is effective, but many are concerned with FDA process

Pharmalot By Ed Silverman

Billions spent on prescription drug ads may have increased Medicare spending

Pharmalot By Ed Silverman

Pharmalittle: CureVac Covid-19 shot was 47% effective in a trial; pricey brain cancer drug no longer covered by Medicare

Pharmalot By Ed Silverman

Planned changes at Soros’ Open Society has access-to-medicines advocacy groups on edge

Pharmalot By Ed Silverman

Pharmalittle: Regeneron Covid-19 drug cuts risk of death in some patients; bills reintroduced to help develop new antibiotics

Pharmalot By Ed Silverman

Pharmalittle: AstraZeneca antibody therapy failed to prevent Covid-19; former FDA Commish Hahn joins Moderna backer

Pharmalot By Ed Silverman

Pharmalittle: Novavax says Covid-19 shot is highly effective; doctors scramble to advise patients on Alzheimer’s drug

Pharmalot By Ed Silverman

Pharmalittle: A third FDA panel member resigns over Alzheimer’s drug approval; agency’s decision hardens opposition to Woodcock

Pharmalot By Elizabeth Cooney

Pharmalittle: U.S. to donate 500 million Covid vaccine doses; WTO to step up talks on waiving IP protection for Covid shots

Pharmalot By Ed Silverman

WTO members agree to step up talks about Covid-19 intellectual property proposals

Pharmalot By Ed Silverman

Pharmalittle: Biogen and FDA at odds over a key Alzheimer’s drug trial; Senate Dems craft their own drug-pricing bill

Pharmalot By Ed Silverman

Regeneron shareholders urged to boot board member over executive pay practices

Pharmalot By Ed Silverman

Pharmalittle: FDA rewrites rulebook in approving Alzheimer’s drug; Biogen’s price for the drug will strain Medicare

Pharmalot By Ed Silverman

Pharmalittle: AstraZeneca sues Glaxo over a big-selling cancer drug; EU offers rival plan to Covid-19 IP waiver

Pharmalot By Ed Silverman

EU pushes rival plan to Covid-19 vaccine IP waiver, but some deride it as ‘meaningless’

Pharmalot By Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot By Ed Silverman

Pharmalittle: A turnaround artist hopes to revamp a former Shkreli company; will the FDA approve Biogen’s Alzheimer’s drug?

Pharmalot By Ed Silverman

After repeated losses in the U.S., Catalyst wins a victory in Canada over a rare disease drug

Pharmalot By Ed Silverman

Former Celgene shareholders claim Bristol Myers reaped a $6.4 billion windfall by delaying a drug approval

Pharmalot By Ed Silverman

Pharmalittle: Purdue bankruptcy plan clears a major hurdle; Senate Finance chair probes AbbVie over taxes

Pharmalot By Ed Silverman

Senate finance chair investigates AbbVie over its corporate tax strategy

Pharmalot By Ed Silverman

Industry payments to doctors are associated with increased prescribing of long-acting insulin

Pharmalot By Ed Silverman

Pharmalittle: JAMA editor stepping down after podcast furor; global agencies urge $50 billion investment to fight Covid-19

Pharmalot By Ed Silverman

Most Read

‘Simply unacceptable’: Alzheimer’s Association blasts Biogen over the price of its new medicine

Mississippi becomes the first state to jointly sue drug makers and PBMs over the cost of insulin

‘A litany of flaws’: Advocacy group urges HHS to boot FDA officials over Alzheimer’s drug approval

Lawmakers revive legislation to accelerate the development of new antibiotics

Up and down the ladder: The latest comings and goings

‘The price is bewildering’: The cost of Biogen’s Alzheimer’s drug may lead payers to erect roadblocks

American Medical Association delegates vote to support controversial Covid-19 IP waiver

Centene to pay $143 million to two states to settle allegations of overcharging Medicaid

All Coverage

Pharmalittle: Biden to spend $3 billion to develop Covid-19 pills; most Americans believe the new Alzheimer’s drug will be effective

Poll: Most Americans believe new Alzheimer’s drug is effective, but many are concerned with FDA process

Billions spent on prescription drug ads may have increased Medicare spending

Pharmalittle: CureVac Covid-19 shot was 47% effective in a trial; pricey brain cancer drug no longer covered by Medicare

Planned changes at Soros’ Open Society has access-to-medicines advocacy groups on edge

Pharmalittle: Regeneron Covid-19 drug cuts risk of death in some patients; bills reintroduced to help develop new antibiotics

Pharmalittle: AstraZeneca antibody therapy failed to prevent Covid-19; former FDA Commish Hahn joins Moderna backer

Pharmalittle: Novavax says Covid-19 shot is highly effective; doctors scramble to advise patients on Alzheimer’s drug

Pharmalittle: A third FDA panel member resigns over Alzheimer’s drug approval; agency’s decision hardens opposition to Woodcock

Pharmalittle: U.S. to donate 500 million Covid vaccine doses; WTO to step up talks on waiving IP protection for Covid shots

WTO members agree to step up talks about Covid-19 intellectual property proposals

Pharmalittle: Biogen and FDA at odds over a key Alzheimer’s drug trial; Senate Dems craft their own drug-pricing bill

Regeneron shareholders urged to boot board member over executive pay practices

Pharmalittle: FDA rewrites rulebook in approving Alzheimer’s drug; Biogen’s price for the drug will strain Medicare

Pharmalittle: AstraZeneca sues Glaxo over a big-selling cancer drug; EU offers rival plan to Covid-19 IP waiver

EU pushes rival plan to Covid-19 vaccine IP waiver, but some deride it as ‘meaningless’

Up and down the ladder: The latest comings and goings

Pharmalittle: A turnaround artist hopes to revamp a former Shkreli company; will the FDA approve Biogen’s Alzheimer’s drug?

After repeated losses in the U.S., Catalyst wins a victory in Canada over a rare disease drug

Former Celgene shareholders claim Bristol Myers reaped a $6.4 billion windfall by delaying a drug approval

Pharmalittle: Purdue bankruptcy plan clears a major hurdle; Senate Finance chair probes AbbVie over taxes

Senate finance chair investigates AbbVie over its corporate tax strategy

Industry payments to doctors are associated with increased prescribing of long-acting insulin

Pharmalittle: JAMA editor stepping down after podcast furor; global agencies urge $50 billion investment to fight Covid-19

FTC issues a non-committal report on ‘rebate walls,’ but will the agency dig deeper?